Draft guidance from NICE has recommended ranibizumab as an option for treating visual impairment caused by diabetic macular oedema (DMO). NICE conducted a rapid review of the original guidance, published in November 2011, because the manufacturer submitted a revised Patient Access Scheme, together with updated analyses including the drug's superior relative effect among a sub-group of people with DMO.
The appraisal consultation document (ACD) makes the following recommendations:
1. Ranibizumab is recommended as an option for treating visual impairment due to diabetic macular oedema only if:
the person has a central retinal thickness of 400 micrometres or more and
the manufacturer provides ranibizumab with the discount agreed as part of the patient access scheme (as revised in 2012).
2. People currently receiving ranibizumab who do not have a central retinal thickness of 400 micrometres or more should be able to ...